AbbVie: FDA approval in ulcerative colitis

(CercleFinance.com) - AbbVie announces that the US FDA has approved its Skyrizi for adults with moderate to severe active ulcerative colitis, bringing to four the product's indications in immune-mediated inflammatory diseases.


With over one million people living with ulcerative colitis, the US has one of the largest populations affected by this disease, and the numbers continue to grow, the healthcare group highlights.

This approval is supported by two Phase III clinical trials, which showed that clinical remission, the primary endpoint, was achieved at the same time as endoscopic improvement, the key secondary endpoint.


Copyright (c) 2024 CercleFinance.com. All rights reserved.